Matthew Winton - 25 Jun 2025 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role
COO
Signature
/s/ Sanjay Subramanian, as attorney-in-fact for Matthew Winton
Issuer symbol
INZY
Transactions as of
25 Jun 2025
Net transactions value
+$10,623
Form type
4
Filing time
27 Jun 2025, 16:05:19 UTC
Previous filing
02 Apr 2025
Next filing
03 Jul 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Winton Matthew COO C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON /s/ Sanjay Subramanian, as attorney-in-fact for Matthew Winton 27 Jun 2025 0001971400

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INZY Common Stock Award $10,623 +14,355 +194% $0.7400 21,743 25 Jun 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period.